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Healing Venom
Vipers, induding some 200 species ofser-
pents within the family Viperidae, are not
the cuddliest of creatures. Ranging in
length from the foot-long Orsini viper to
the dreaded bushmaster, which can grow
to more than 10 feet, all feature long, hol-
low fangs designed for poisoning prey. Yet,
researchers suggest that the venom ofthese
deadly reptiles may offer an array ofheal-
ing agents.
At the University of Delaware in
Newark, for example, Mary Ann McLane,
an assistant professor in the department of
medical technology, is studying the chemi-
cal structure ofa viper venom protein that
seems to stop the spread oftumors in labo-
ratory mice. Ifher work pans out, it could
lead to new antitumor drugs, according to
her collaborator, Stefan Niewiarowski, a
professor in the department ofphysiology
and the Sol Sherry Thrombosis Research
Center at the Temple University School of
Medicine in Philadelphia, Pennsylvania.
McLane is among a growing number
of academic, government, and industrial
researchers who are investigating venom-
based disintegrins-proteins that interact
with integrins, the biochemical hooks on
cell surfaces that "allowcells to talk to each
other," explains Steven Houser, former
president of the American Heart
Association (AHA) in southeastern
Pennsylvania and a professor ofphysiology
atTemple.
Why study these
viper venom pro--
teins? When a viper
bites, McLane says,
its venom prevents*
blood from clotting
by blocking the m
sticky protein fib-
rinogen from bind-
ingwith platelets. Indeed,
Niewiarowski says, disin-
tegrins are potent
inhibitors of platelet
aggregation and cell
adhesion, and since the
late 1980s, studies of the
venom-based proteins
have focused primarily on
their promise as anticoag-
ulants. Around 1986,
Niewiarowski teamed up
with Tur Fu Huang,
chairman ofthe department ofpharmacol-
ogy at the National University of Taiwan
in Taipei, to investigate the exact mecha-
nisms by which disintegrins keep platelets
from forming clusters.
Then, in 1995, a research team directed
byVincent L. Morris, an associate professor
in the department of microbiology and
immunology at the University ofWestern
Ontario in London, Canada, discovered
that the disintegrin eristostatin-produced
by Macmahon's viper (Eristocophis macma-
honi) ofAfghanistan and Pakistan-dra-
matically reduces the spread ofliver tumors
in mice. When mice injected with
melanoma cells were also given eristostatin,
the average number of liver tumors
dropped from 14.4 to 0.6 within 11 days,
according to McLane, who collaborated
with Morris and Niewiarowski on this
work, published in the August 1995 issue
ofExperimentalCellResearch.
Since then, McLane has been compar-
ing the structure oferistostatin with echis-
tatin, adisintegrin from the Middle Eastern
saw-scaled viper (Echis carinatus). The goal,
she says, is to learn why eristostatin is so
much more effective than echistatin at
blocking fibrinogen interactions and pre-
venting the spread ofmelanoma cells. The
two disintegrins are 68% identical, and
both feature a protruding section ofamino
acids known as the RGD loop. Composed
ofarginine, glycine, and aspartic acid, the
- RGD loop apparently
plays a major role in all
interactions with inte-
grins. When McLane
Viper VIP. New research shows that venom from MacMahon's viper contains eristostatin
(top left), a substancethatmay reducethe spread oftumors.
altered just three of the 13 amino acids in
echistatin's RGD loop, she was able to
make the protein behave more like its
cousin, eristostatin. Once she fully under-
stands these structural differences, McLane
says, a synthetic version of eristostatin
might offer therapeutic properties.
McLane says she plans to study eristo-
statin's effecton metastaticmelanomacells in
collaboration with Mary E. Miele, an assis-
tant professor ofmedical technology at the
UniversityofDelaware. Inaddition, McLane
hasjoined forces with Norma Staiano, apro-
fessor of biochemistry at the Universita di
Napoli Federico II in Italy, who discovered
that echistatin-likeeristostatin-can inhibit
the spread of lung cancer cells in mice.
Staiano's workwas published in the October
1997 issue of the InternationalJournal of
Oncology. OfMcLane's research Staiano says,
"Her work has been pivotal to highlight the
structural features other than the RGD locus
that determine the specificity ofdisintegrins
for integrin receptors on platelet andcell sur-
faces.
Dozens of pharmaceutical companies
are investigating disintegrins, Houser says.
At Merck Research Laboratories ofWest
Point, Pennsylvania, for instance, re-
searchers such as Bohumil Bednar are
already usingsyntheticversions ofthe RGD
loop to study blood clotting events. Bednar
declined to comment on the work, but his
research, published in the August 1997
issue ofMolecularPharmacology, describes a
technique for using RGD "mimics" as a
probe for identifying key binding sites on
the integrin alphaIIb beta3 in human kid-
ney cells. Niewiarowski and
j manyothers, meanwhile, are
using a similar technique to
develop synthetic versions of
alphaIIb beta3 antagonists,
which strongly inhibit
platelet aggregation.
Most disintegrin
research has been funded
by the AHA and the
National Institutes of
Health. The AHA initially
supported the work because
snake venoms inhibit the
coagulation process, and
blood clots can play a role
in heart attacks, strokes,
and other cardiovascular
diseases, Houser says. But
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the research has since produced crucial
fundamental insights. As researchers zero
in on the specific amino-acid sequences
that bind with integrins, he says, they've
developed a molecular probe for better
understanding communication between
cells. "When that information transfer
becomes dysfunctional," he notes, "it can
induce disease states."
Bird Flu Vaccine
In the race to develop vaccines against an
ever-widening array of infectious diseases,
Aviron, a biopharmaceutical research and
development company located in
Mountain View, California, may be lead-
ing by a nose. Working in collaboration
with the National Institutes ofHealth and
the Centers for Disease Control and
Prevention, Aviron is developing a novel
technology in antiviral vaccinations: the
cold-adapted live influenza vaccine. A
major advantage of the new technology is
that the vaccine may be administered
through a nasal spray, bypassing the need
for injections. Currently, Aviron is using
its technology to develop two candidate
vaccines against the avian A/Hong
Kong/97 (H5N1) influenza virus, more
commonlyknown as the "bird flu."
The bird flu, which first appeared in
humans in May 1997, is the latest in a
string ofwhat are known as "Hong Kong
flu" epidemics-outbreaks that start in
southeast China, where the densely packed
population lives cheek to beak with large
numbers of chickens, ducks, and other
poultry. It is believed that the birds carry
various viral strains that are then transmit-
ted somehow-perhaps through pig inter-
mediaries-to humans. Scientists aren't
sure why or how the viruses cross over to
humans, but the results in the past have
been devastating, as evidenced by out-
breaks such as one in 1968 that killed
thousands worldwide. In December, Hong
Kong officials launched what appears to
have been a successful strike against the
disease by slaughtering over 1 million
chickens and otherpoultry.
Martin Bryant, vice president of
research for Aviron, says, "With the elimi-
nation ofthe Hong Kong poultry popula-
tion, the epidemic was aborted; the virus
never got up the steam to pass from one
person to another. What happens is that a
virus may be modified as it passes from
person to person, and that did not occur.`
Still, says Bryant, although the bird flu
didn't spread to epidemic proportions this
time, it's not a matter ofwhether such an
epidemic will come, but when-and pub-
lic health officials should be prepared.
Friend or fowl? A new vaccine technology may
prevent outbreaks of the avian A/Hong Kong/97
influenza virus, or 'bird flu," which has recently
begun to appear in humans.
Aviron scientists are using a "reverse
genetics," or recombinant, approach to
introduce specific protective genes into an
attenuated (weakened) master donor virus
strain from which all flu vaccines are devel-
oped. The vaccine could also be used as a
platform to prepare an inactivated version
ofthevaccine in large quantities.
Aviron's live-virus vaccines are attenu-
ated viruses that are adapted to grow in the
relatively cool nasal region as well as in the
lungs. The cold-adapted flu virus triggers
an immune response at the place of entry
of the influenza virus, leaving the vaccine
recipient free of flu but armed with
immune capabilities to combat future
attacks by thevirus.
Exposure to the flu is believed to occur
largely through inhalation ofdroplets con-
taining the live virus, and some view the
nasal spray asworking directly at the site of
infection. In a 1997 trial of 1,602 children
aged six years and younger, the nasal spray
vaccine showed an amazing 93% efficacy
rate against culture-confirmed influenza.
This efficacy rate may be due to the fact
that spraying the vaccine in the nose stim-
ulates the mucosal antibodies found in the
nose, throat, and mouth, and circulating
antibodies in the bloodstream. These anti-
bodies are an added boost to the cell-medi-
ated immune responses triggered by the
traditional flu shot.
The absence of needles is seen as an
advantage in getting the vaccine to people
who are afraid of shots, particularly chil-
dren, who are one ofthe primaryvectors of
influenza. Says Bryant, "The first wave of
anyepidemic in acommunity usually starts
with kids." Plus, because it's a simple nose-
spray, the vaccine wouldn't need to be
administered by a health-care professional.
Eventually, the vaccine may even be avail-
able overthe counter.
The Aviron live-virus vaccine is cur-
rently undergoing late Phase III trials. The
company hopes to present its product for
license review by the Food and Drug
Administration by mid-1998. Although a
bird flu epidemic appears to have been
temporarily staved off, Bryant says, "We
may not use it this time, but there will be a
time when we will. We are working hard
to be ready before it comes."
The State of the Science on
Endocrine Disruptors
As research on endocrine-disrupting chemi-
cals flourishes worldwide, international
groups are working to coordinate research
activities being conducted by organizations
around the globe. The International
Programme on Chemical Safety (IPCS), a
collaborative program ofthe World Health
Organization (WHO), the International
Labour Organization, and the United
Nations Environment Programme, is lead-
ing an effort to conduct a global inventory
ofongoing research activities related to the
health and ecological effects of endocrine-
disrupting chemicals, and is working to
develop an international assessment of the
state ofthe science on endocrine disruptors.
The Organisation for Economic Co-opera-
tion and Development (OECD) is leading
international efforts on delineating testing
methods for endocrine disruptors.
On 16-18 March 1998, the IPCS, in
coordination with the OECD, convened a
joint meeting in Washington, DC, with a
steering committee of scientific experts to
provide guidance for these projects. The
steering group was made up ofrepresenta-
tives from Canada, Finland, Germany,
Italy, Sweden, the Netherlands, Mexico,
Japan, the United Kingdom, and the
United States. The objectives of the meet-
ing were to discuss the structure and con-
tent of the global inventory and to define
the objectives and scope ofthe internation-
al state ofthe science assessment document,
as well as develop an oudine and guidelines
fordevelopment ofthe document.
Participants wereasked todiscuss awork-
ing definition for endocrine-disrupting
chemicals, and it was agreed to define an
endocrine disruptor as an exogenous sub-
stance or mixture that alters the function of
the endocrine system and consequently caus-
esadversehealth effects in an intact organism
or its progeny or subpopulations. Apotential
endocrine disruptor is defined as an exoge-
nous substance or mixture that possesses
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